This observational study will examine changes in brain-region size, shape, and activity that occur in women with breast cancer and how those changes relate to the development of mild cognitive impairment. Three groups will be compared: women with breast cancer who will undergo hormonal therapy with or without chemotherapy, women with breast cancer who will undergo no therapy or radiation therapy, and healthy female volunteers.
|Min Age||Max Age||Gender||Healthy Volunteers|
Accepts Healthy Volunteers
This study aims to identify neuroimaging biomarkers—specifically, measures of the brain's hippocampal-cortical integrity—that can predict mild cognitive impairment in female breast cancer patients who receive chemotherapy and/or hormonal therapy. These therapies increase long-term survival but produce changes in cognitive function, sometimes as soon as 3 months after treatment, in an average of 30 percent of women with breast cancer. Early identification of women at risk for developing treatment-related cognitive impairment is needed to develop potential prevention or treatment options and prevent further decline.
Although neuroimaging studies have identified brain changes associated with chemotherapy ("chemo brain"), none has assessed the type and severity of such changes following hormonal therapy. No study has determined which individuals are at greatest risk for cognitive impairment.
|Map Marker||City||State||Zip Code||Status||Primary Contact|
Geolocation is 41.8925085, -87.6161696
National Institute of Nursing Research (NINR)
Lei Wang, PhD